Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common
-
Shares outstanding
-
7,989,235
-
Total 13F shares
-
1,263,487
-
Share change
-
-468,822
-
Total reported value
-
$1,869,962
-
Price per share
-
$1.48
-
Number of holders
-
19
-
Value change
-
-$1,075,287
-
Number of buys
-
6
-
Number of sells
-
8
Institutional Holders of Traws Pharma, Inc. - Common (TRAW) as of Q2 2025
As of 30 Jun 2025,
Traws Pharma, Inc. - Common (TRAW) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,263,487 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vestal Point Capital, LP, Alyeska Investment Group, L.P., GEODE CAPITAL MANAGEMENT, LLC, Ikarian Capital, LLC, TWO SIGMA SECURITIES, LLC, TWO SIGMA INVESTMENTS, LP, VANGUARD GROUP INC, and BlackRock, Inc..
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.